肾康栓联合尿毒清改善腺嘌呤造模慢性肾衰竭SD大鼠肾功能探索

Research of Mechanism of Shenkang Suppository Combined with Niaoduqing Ameliorating Renal Function of Chronic Renal Failure Rats Induced by Adenine

目的观察肾康栓肛门给药联合口服尿毒清颗粒对于口服腺嘌呤造模慢性肾衰竭雄性SD大鼠肾功能的改善作用。方法慢性肾衰竭SD雄性大鼠模型由腺嘌呤悬浊液200 mg/(kg·d)灌胃制备。以尿毒清颗粒作为口服途径对照药物。实验分组为联合用药组、肾康栓组、尿毒清组、模型组(造模后予以纯净水灌胃即安慰剂组)、空白组(未造模)。肾康栓组予以肾康栓隔日一次1/3粒(1. 0 g)送入肛门+纯净水15 mL/kg日一次灌胃。联合用药组予以肾康栓隔日一次1/3粒(1. 0g)送入肛门+尿毒清颗粒纯净水溶液15 mL/kg每日一次灌胃。尿毒清组予以尿毒清颗粒纯净水溶液15 mL/kg每日一次灌胃+纯净水13 mL/L隔日一次灌肠。模型组及空白组均予以纯净水15 mL/kg每日一次灌胃+纯净水13 mL/kg隔日一次灌肠。给药周期持续14 d,届时将于眼静脉取静脉血、肾组织、空肠组织作为标本,将实验SD大鼠血清中的血肌酐(SCR)尿素氮(BUN)尿素(UA)血β2微球蛋白(β2-MG)血清白蛋白(ALB)肿瘤坏死因子α(TNF-α)水平以及肾组织URAT1和空肠组织ABCG2的表达水平作为观察指标。结果①肾康栓组和联合用药组SCR、BUN、UA、TNF-α较尿毒清组及模型组呈明显低值,(P <0. 05),而肾康栓组与联合用药组之间无统计学差异。②联合用药组β2-MG水平明显低于肾康栓组、尿毒清组及模型组(P <0. 05)但肾康栓组、尿毒清组及模型组之间并不存在统计学差异(P> 0. 05)。③肾康栓组、联合用药组、尿毒清组及模型组各组之间均不存在ALB差异(P> 0. 05)。④肾康栓组和联合用药组肾组织URAT1蛋白表达明显低于尿毒清组及模型组(P <0. 05)。而肾康栓组与联合用药组之间、尿毒清组与模型组之间均不存在统计学差异(P> 0. 05)。⑤联合用药组、肾康栓组、尿毒清组及模型组之间空肠ABCG2均无统计意义的差异(P> 0. 05)。结论肾康栓可通过肠系膜毛细血管吸收后实现其化瘀消浊的改善肾功能效用。具化体现为:消除尿液中小分子毒素、抑制炎症因子活动、加速尿酸排出三个方面。

Objective To observe the effects of Shenkang Suppository combined with Niaoduqing ameliorating renal function of chronic renal failure (CRF) rats induced by adenine. Methods CRF rats model was built by 200 mg/ (kg·d) adenine by gavage. Sixty rats were divided into combination group,Shenkang Suppository group,Niaoduqing group,model group and blank group. The Shenkang Suppository group was given Shenkang Suppository 1/3 granule (1. 0 g) by anal administration every other day + 15 mL/kg water by gavage once a day. The combination group was given given Shenkang Suppository 1/3 granule (1. 0 g) by anal administration every other day + 15 mL/kg Niaoduqing Granules by gavage once a day. The Niaoduqing group was given 15 mL/kg Niaoduqing solution by gavage once a day + 13 mL/kg water by enema every other day. The model and blank groups were given 15 mL/kg water by gavage once a day + 13 mL/kg water by enema every other day. After 14 days treatment,levels of serumcreatinine (SCR),urea nitrogen (BUN),uric acid (UA),serum levels of β2 microglobulin (β2-MG),albumin (ALB),tumor necrosis factor α (TNF-α) and URAT1 expression in nephridial tissues and ABCG2 expression in Jejunum tissues were measured and analyzed. Results ①The levels of SCR,BUN,UA and TNF-α of the combination group and Shenkang Suppository group were obviously lower than those of the Niaoduqing group and model group (P < 0. 05),while there was no statistical significance between combination group and Shenkang Suppository group. ②The level of β-MG of combination group was lower obviously than that of the Shenkang Suppository group and model group (P < 0. 05),while no statistical significance among Shenkang Suppository group,Niaoduqing group and model group (P > 0. 05) . ③The levels of ALB of combination group,Shenkang Suppository group,Niaoduqing group and model group were significant (P < 0. 05) . ④The URAT1 protein expressions of Shenkang Suppository group and combination group were obviously lower than those of Niaoduqing group and model group (P < 0. 05). There was no significance between Shenkang Suppository group and combination group or between Niaoduqing group and model group (P > 0. 05) . ⑤There was no statistically significant difference of ABCG2 in jejunum tissues among combination group,Shenkang Suppository group,Niaoduqing group and model group (P > 0. 05). Conclusion Shenkang Suppository could exert the effect of improving renal function after intestinal absorption,which was specifically exerted in three aspects: removing small and medium-sized molecules of urine toxin,reducing inflammatory factors and promoting the excretion of uric acid.